<div id="readability-page-1"><h3>Claim 70% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) just unveiled an update. ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has completed enrollment of 133 patients for the interim analysis of its Phase III clinical trial of IMM01 (Timdarpacept) as a first-line treatment for chronic myelomonocytic leukemia. The trial builds on prior recognition of IMM01, which in combination with azacitidine has received orphan-drug designation from the U.S. Food and Drug Administration for this indication. IMM01 (Timdarpacept) is engineered to block the CD47 “don’t eat me” signal while engaging Fc-gamma receptors to enhance macrophage-mediated anti-tumor activity, and its design avoids binding to human red blood cells, supporting a favorable safety profile. Successful progress in this late-stage study could strengthen ImmuneOnco’s position in the global immuno-oncology market and enhance the value of its patent-protected CD47-targeting platform for patients and investors, although clinical and commercialization risks remain. The most recent analyst rating on (HK:1541) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H stock, see the HK:1541 Stock Forecast page. More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a China-based biopharmaceutical company focused on innovative immuno-oncology therapies. Its core product, IMM01 (Timdarpacept), is a first-in-class SIRPα-Fc fusion protein targeting CD47, designed to activate macrophages and treat hematologic malignancies such as chronic myelomonocytic leukemia, with global intellectual property and commercial rights held by the group. Average Trading Volume: 1,723,080 Technical Sentiment Signal: Sell Current Market Cap: HK$3.86B </div>

516820

516930

159849

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has completed enrollment of 133 patients for the interim analysis of its Phase III trial of IMM01 (Timdarpacept) for chronic myelomonocytic leukemia. The drug has received orphan-drug designation from the FDA and aims to enhance anti-tumor activity while maintaining safety. Successful trial results could strengthen ImmuneOnco's position in the immuno-oncology market. The latest analyst rating for the stock (HK:1541) is a Hold with a price target of HK$4.50.

Tip Ranks

Ping An CSI Medicine and Medical Device Innovation ETF

Minsheng Royal CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

E Fund CSI 300 Health Care ETF

ICBCCS SSE STAR Biology and Medicine ETF

IMMUNEONCO-B

E Fund CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Yinhua CSI Innovative Drugs Industry ETF

ChinaAMC CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Tianhong CNI BIOMEDICINE ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Huaan Hang Seng Biotech ETF

ImmuneOnco Completes Key Patient Enrollment in Phase III Trial of Lead Cancer Drug IMM01